MintNeuro has signed a partnership with Motif Neurotech to advance the development of miniature brain-computer interface (BCI) therapy for mental health conditions.
The collaboration will bring together MintNeuro’s specialised, low-power neural interface chips and Motif Neurotech’s clinical-stage implant platform, paving the way for new developments in therapeutic BCIs for mental health.
It aims to rapidly move these technologies towards clinical application in conditions such as depression and bipolar disorder.
The agreement gives Motif Neurotech access to MintNeuro’s miniaturised sensing and stimulation integrated circuits, which will be closely aligned with the former’s clinical device plans.
As part of a multi-year commercial supply agreement, Motif Neurotech will incorporate MintNeuro’s neural interface integrated circuits throughout pre-clinical, early clinical, and pivotal trial phases.
MintNeuro will benefit from extensive real-world system validation and ongoing feedback on chip requirements from Motif Neurotech’s device progression.
MintNeuro CEO and co-founder Dorian Haci said: “Motif is a visionary partner that is pushing the boundaries of what is technically and clinically possible in this emerging space, and that is exactly the kind of collaboration our technology is built for.
“Our formal co-operation is also a clear signal that the treatment of mental health conditions is moving into a phase where scalable, chip-based platforms can start to be applied commercially at scale, and play a central role in enabling new therapies that can improve quality of life for patients everywhere.”
The companies' partnership has progressed from joint system architecture to active hardware validation, with MintNeuro’s sensing chip being integrated into Motif Neurotech’s devices used in pre-clinical work.
The collaboration will align future chip generations with Motif Neurotech’s clinical milestones, moving from high-performance sensing to comprehensive stimulation functionality.
Motif Neurotech recently received approval from the US Food and Drug Administration (FDA) to start a clinical trial aimed at addressing treatment-resistant depression (TRD).
